INDIANAPOLIS, Sept. 15, 2020 /PRNewswire/ -- Eli Lilly and
Company (NYSE: LLY) has launched an open innovation challenge for
individuals and teams across the United
States to submit inspiring digital health solutions that can
help make life better for people living with atopic dermatitis. The
challenge, "Transforming Atopic Dermatitis
Care: Enhancing Quality of Life and Patient Care
for People Living with Inflammatory Skin Diseases," focuses on
leveraging digital technologies to enhance care and improve health
and well-being for people with inflammatory skin diseases. The
submission site, including additional details about the challenge's
criteria, eligibility and requirements, is available at
www.lilly.com/atopicdermchallenge.
"Lilly is committed to advancing digital solutions that can give
people greater control over their health. Atopic dermatitis is more
than skin deep and can have a devastating impact for those who
suffer from it," said Rich Carter,
Lilly's chief digital officer. "Innovation challenges provide a
great opportunity to help uncover bold and scalable digital
solutions from anyone within the health tech community, including
students, patients, caregivers, entrepreneurs, small-medium sized
business and others."
This innovation challenge is calling for novel technology-based
digital solutions – mobile apps, sensors and wearables, connected
drug delivery devices, real-time monitoring, algorithms, digital
games, etc. – that are either conceptual or in early stages of
development, with potential to make a meaningful difference in
transforming the care for those living with inflammatory skin
diseases, such as atopic dermatitis.
Eligible individuals, teams and organizations are encouraged to
participate. Submissions will be accepted through 11:59 p.m. EDT on Oct. 21,
2020. A panel of Lilly experts will evaluate all submissions
and select five finalists by Nov. 20,
2020. The finalists will be selected based on the idea's
potential impact, creativity, technical feasibility and ability to
address the longer-term needs of people with atopic dermatitis.
The finalist with the winning idea, subject to the submissions
received, will be announced in December and will be
awarded $50,000 along with the potential opportunity to
co-develop the solution with Lilly. Interested participants can
learn more and enter at www.lilly.com/atopicdermchallenge.
About Atopic Dermatitis
Atopic dermatitis (AD), or
atopic eczema, is a chronic, relapsing skin disease characterized
by intense itching, dry skin and inflammation that can be present
on any part of the body.[i] AD is a heterogeneous
disease both biologically and clinically, but may be characterized
by chronic symptoms of itch, redness and skin damage that are often
punctuated with episodic, sometimes unpredictable, flares or
exacerbations.[ii],[iii] AD affects
approximately 1-3% of adults worldwide.[iv]
Moderate to severe AD is characterized by intense itching,
resulting in visibly damaged skin.[v] Like other chronic
inflammatory diseases, AD is immune-mediated and involves a complex
interplay of immune cells and inflammatory
cytokines.[vi]
About Lilly in Dermatology
By following the science
through unchartered territory, we continue Lilly's legacy of
delivering innovative medicines that address unmet needs and have
significant impacts on people's lives around the world.
Skin-related diseases are more than skin deep. We understand the
devastating impact this can have on people's lives. At Lilly, we
are relentlessly pursuing a robust dermatology pipeline to provide
innovative, patient-centered solutions so patients with
skin-related diseases can aspire to live life without
limitations.
About Eli Lilly and Company
Lilly is a global
health care leader that unites caring with discovery to create
medicines that make life better for people around the world. We
were founded more than a century ago by a man committed to creating
high-quality medicines that meet real needs, and today we remain
true to that mission in all our work. Across the globe, Lilly
employees work to discover and bring life-changing medicines to
those who need them, improve the understanding and management of
disease, and give back to communities through philanthropy and
volunteerism. To learn more about Lilly, please visit us at
lilly.com and lilly.com/newsroom. C-LLY
[i] Zuberbier T, Orlow SJ, Paller AS, et al. Patient
perspectives on the management of atopic dermatitis. The Journal of
Allergy and Clinical Immunology. 2006;118: 226-32.
[ii] Thijs JL, Strickland I, Bruijnzeel-Koomen C,
et. al. Moving toward endotypes in atopic dermatitis:
identification of patient clusters based on serum biomarker
analysis. The Journal of Allergy and Clinical Immunology. 2017.
[iii] Langan SM, Thomas
KS, Williams HC. What is meant by "flare" in atopic
dermatitis? A systematic review and proposal. Arch Dermatol.
2006;142:1190-1196.
[iv] Nutten S. Atopic dermatitis: global epidemiology
and risk factors. Annals of Nutrition and Metabolism. 2015;66(suppl
1): 8-16.
[v] Yosipovitch G, Papoiu AD. What causes itch in atopic
dermatitis? Current Allergy and Asthma Reports. 2008;8:306-311.
[vi] Weidinger, S, Novak, N. Atopic dermatitis. The
Lancet Volume 387. 2016;10023:1109-1122.
Refer to: Karen Glowacki;
kglowacki@lilly.com;
317-370-1177
View original content to download
multimedia:http://www.prnewswire.com/news-releases/lilly-launches-digital-health-open-innovation-challenge-to-help-transform-atopic-dermatitis-care-301130627.html
SOURCE Eli Lilly and Company